DENVER--(BUSINESS WIRE)--The costs and timelines to conduct clinical trials continue to increase, as does study complexity. While much of the focus in clinical trials has been on improving data quality and overall study efficiency addressing cost/timeline/complexity issues, less attention has been paid to the impact of patient poor compliance for self-administered study drugs.
It’s estimated that after just 3 months on trial, patient dose compliance drops to 75 percent and at 10 months, that compliance rate drops to 60 percent. ClinOne’s Dosing Manager provides several options to engage patients including web-based notifications, interactive mobile text messages, and dosing calendars to keep patients on track and compliant.
By engaging the patients, ClinOne compliance rates are maintained at an astounding 99% (with ranges from 95% to 99%). “We are incredibly proud to contribute the impact on clinical trials. It’s estimated that 91 percent of mobile users keep their phone within arm’s reach 24/7, while 90 percent of all text messages are read within three minutes of receipt, so this is a highly effective means of engaging the patient and driving better dose compliance,” says Rob Bohacs, ClinOne’s founder and CEO.
About ClinOne
ClinOne offers a complete suite of mobile and web applications to enhance patient, family, caregiver and site engagement. Currently, our solutions help support nearly 3,000 clinical studies across 1,900 research sites in 55 countries. To learn more or to schedule a demo, please contact us. Visit www.clinone.com for more information.
